For those affected by ME/CFS, Long COVID, and other infection-associated chronic illnesses (IACIs), finding access to effective treatments remains a significant challenge. These conditions impact millions of people globally, yet therapeutic options are still limited.
The need for greater accessibility to treatment options can’t be overstated, as so many are left managing symptoms with few resources and minimal guidance. At Renegade Research, we know that this gap in care calls for urgent attention, and we’re committed to supporting initiatives that accelerate research and access.
Organizations and advocacy groups worldwide are uniting to drive change. From crowdfunding studies to advocating for policy changes, a collective momentum is growing, fueled by researchers, patients, and advocates alike. Notably, initiatives like the Open Medicine Foundation’s research on cellular energy production and Solve ME/CFS’s advocacy efforts exemplify this push. The continued success of these programs relies on the unified goal of bringing treatments to those who need them most.
One initiative that’s gaining traction in the U.S. is the Long COVID Moonshot Act. This forward-thinking piece of legislation aims to fast-track research funding and prioritize therapeutic development for long COVID and related conditions like ME/CFS. With its ambitious goals, the Long COVID Moonshot Act could significantly expand research resources and therapeutic trials, moving us closer to viable treatment solutions.
Today we want to highlight how the ME/CFS, Long COVID and IACI communities are tirelessly working to bring awareness to these complex conditions and help accelerate access to therapeutics.
Through advocacy, education, and support, they are guiding efforts to ensure that affected individuals receive the recognition and care they deserve.
Just doing this in today's society is incredibly hard, but we also do this while, in many cases, we're suffering from incapacitating symptoms ourselves.
We see you, we are here for you, we are you.
Thank you.
Let's keep up the momentum going!
Speak soon,
The Renegade Research Team